New 90-day results from the US pivotal trial of Medtronic PLC's MiniMed 780G insulin pump show the next-generation system safely improves users’ “time in range” (70-180 mg/dL) – the percentage of time the users’ blood glucose is near the optimal level – without increasing hypoglycemia.
Primary investigator Anders Carlson of the Park Nicollet International Diabetes Center in Minneapolis presented results from the US pivotal...